MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-99 decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 18/October/2014, 6.08 am

Vitamin-based life-extention therapy for Males: Vitamin-E increases male longevity via up regulation of its target gene, 18/October/2014, 5.58 am
October 18, 2014
Physiological and Pathological mechanisms that control glycolysis: IL-1β inhibits glycolysis and cancer progression via down regulation of PDK1, 18/October/2014, 6.13 am
October 18, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based therapy for Alzhemer’s disease and tauopathies: MiRNA-99 decreases tau phosphorylation and ameliorates tau pathology via down regulation of its target gene, 18/October/2014, 6.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance:  It has been shown that decreasing the expression of Tau protein alleviates the pathogenic symptoms-associated with Alzheimer’s disease. This study suggests, for the first time, that MiRNA-99 decreases the phosphorylation of Tau protein and improves the pathological symptoms associated with Tau accumulation. Thus, pharmacological formulations encompassing MiRNA-99 or its activators” can be used to treat patients suffering from Alzheimer’s disease and tauopathies.

Comments are closed.